Skip to main content
Top
Published in: European Journal of Medical Research 1/2013

Open Access 01-12-2013 | Research

Ambulatory care for HIV-infected patients: differences in outcomes between hospital-based units and private practices: analysis of the RESINA cohort

Authors: Mark Oette, Stefan Reuter, Rolf Kaiser, Björn Jensen, Thomas Lengauer, Gerd Fätkenheuer, Heribert Knechten, Martin Hower, Abdurrahman Sagir, Herbert Pfister, Dieter Häussinger, the RESINA study group

Published in: European Journal of Medical Research | Issue 1/2013

Login to get access

Abstract

Background

The efficacy of highly active antiretroviral therapy (HAART) in the treatment of HIV infection is influenced by factors such as potency of applied drugs, adherence of the patient, and resistance-associated mutations. Up to now, there is insufficient data on the impact of the therapeutic setting.

Methods

Since 2001, the prospective multicenter RESINA study has examined the epidemiology of transmitted HIV drug resistance in Nordrhein-Westfalen, the largest federal state of Germany by population. Characteristics of patients treated in hospital-based outpatient units were compared to those of patients treated in medical practices. Longitudinal data of all participants are being followed in a cohort study.

Results

Overall, 1,591 patients were enrolled between 2001 and 2009 with follow-up until the end of 2010. Of these, 1,099 cases were treated in hospital-based units and 492 in private practices. Significant differences were found with respect to baseline characteristics. A higher rate of patients with advanced disease and non-European nationality were cared for in hospital units. Patients in medical practices were predominantly Caucasian men who have sex with men (MSM) harboring HIV-1 subtype B, with lower CDC stage and higher CD4 cell count. Median viral load was 68,828 c/mL in hospital-based units and 100,000 c/mL in private practices (P = 0.041). Only median age and rate of transmitted drug resistance were not significantly different. After 48 weeks, 81.9% of patients in hospital units and 85.9% in private practices had a viral load below the limit of detection (P = 0.12). A similar result was seen after 96 weeks (P = 0.54). Although the baseline CD4 cell count was different (189.5/μL in hospital units and 246.5/μL in private practices, P <0.001), a consistent and almost identical increase was determined in both groups.

Conclusions

The RESINA study covers a large HIV-infected patient cohort cared for in specialized facilities in Germany. Despite significant differences of patients’ baseline characteristics in hospital-based units compared to medical practices, we could not find significant differences in treatment outcome up to 2 years after the initiation of HAART.
Appendix
Available only for authorised users
Literature
1.
go back to reference Robert Koch Institute Berlin: Robert Koch Institute: HIV/AIDS in Deutschland - Eckdaten der Schätzung; 2013. Robert Koch Institute Berlin: Robert Koch Institute: HIV/AIDS in Deutschland - Eckdaten der Schätzung; 2013.
2.
go back to reference Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K, CASCADE Collaboration: Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008, 300: 51–59. 10.1001/jama.300.1.51CrossRefPubMed Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K, CASCADE Collaboration: Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008, 300: 51–59. 10.1001/jama.300.1.51CrossRefPubMed
3.
go back to reference Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, RamalhoMadruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P, STARTMRK Investigators: Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010, 55: 39–48. 10.1097/QAI.0b013e3181da1287CrossRefPubMed Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, RamalhoMadruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P, STARTMRK Investigators: Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010, 55: 39–48. 10.1097/QAI.0b013e3181da1287CrossRefPubMed
4.
go back to reference Pursuing Later Treatment Option II (PLATO II) Project Team; Observational HIV Epidemiological Research Europe (COHERE) Group: Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis 2012, 12: 119–127.CrossRef Pursuing Later Treatment Option II (PLATO II) Project Team; Observational HIV Epidemiological Research Europe (COHERE) Group: Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis 2012, 12: 119–127.CrossRef
5.
go back to reference Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT, International AIDS Society-USA: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304: 321–333. 10.1001/jama.2010.1004CrossRefPubMed Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT, International AIDS Society-USA: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304: 321–333. 10.1001/jama.2010.1004CrossRefPubMed
6.
go back to reference Leisegang R, Maartens G, Hislop M, Sargent J, Darkoh E, Cleary S: A novel Markov model projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public clinics in south Africa. PLoS One 2013, 8: e53570. 10.1371/journal.pone.0053570PubMedCentralCrossRefPubMed Leisegang R, Maartens G, Hislop M, Sargent J, Darkoh E, Cleary S: A novel Markov model projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public clinics in south Africa. PLoS One 2013, 8: e53570. 10.1371/journal.pone.0053570PubMedCentralCrossRefPubMed
7.
go back to reference Nöstlinger C, Page J, Jaccard R, Somaini B, Weber R: Structures of co-operation between an HIV-outpatient clinic and private care physicians. Gesundheitswesen 2003, 65: 90–95. 10.1055/s-2003-37693CrossRefPubMed Nöstlinger C, Page J, Jaccard R, Somaini B, Weber R: Structures of co-operation between an HIV-outpatient clinic and private care physicians. Gesundheitswesen 2003, 65: 90–95. 10.1055/s-2003-37693CrossRefPubMed
8.
go back to reference Oette M, Reuter S, Kaiser R, Lengauer T, Fätkenheuer G, Knechten H, Hower M, Pfister H, Häussinger D, RESINA Study group: Epidemiology of transmitted drug resistance in chronically HIV-infected patients in Germany: the RESINA Study 2001–2009. Intervirology 2012, 55: 154–159. 10.1159/000332015CrossRefPubMed Oette M, Reuter S, Kaiser R, Lengauer T, Fätkenheuer G, Knechten H, Hower M, Pfister H, Häussinger D, RESINA Study group: Epidemiology of transmitted drug resistance in chronically HIV-infected patients in Germany: the RESINA Study 2001–2009. Intervirology 2012, 55: 154–159. 10.1159/000332015CrossRefPubMed
9.
go back to reference Beerenwinkel N, Däumer M, Oette M, Korn K, Hoffmann D, Kaiser R, Lengauer T, Selbig J, Walter H: Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003, 31: 3850–3855. 10.1093/nar/gkg575PubMedCentralCrossRefPubMed Beerenwinkel N, Däumer M, Oette M, Korn K, Hoffmann D, Kaiser R, Lengauer T, Selbig J, Walter H: Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003, 31: 3850–3855. 10.1093/nar/gkg575PubMedCentralCrossRefPubMed
10.
go back to reference Oette M, Kaiser R, Däumer M, Akbari D, Fätkenheuer G, Rockstroh JK, Stechel J, Rieke A, Mauss S, Schmalöer D, Göbels K, Vogt C, Wettstein M, Häussinger D: Primary drug resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res 2004, 9: 273–278.PubMed Oette M, Kaiser R, Däumer M, Akbari D, Fätkenheuer G, Rockstroh JK, Stechel J, Rieke A, Mauss S, Schmalöer D, Göbels K, Vogt C, Wettstein M, Häussinger D: Primary drug resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res 2004, 9: 273–278.PubMed
11.
go back to reference Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009, 4: e4724. 10.1371/journal.pone.0004724PubMedCentralCrossRefPubMed Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009, 4: e4724. 10.1371/journal.pone.0004724PubMedCentralCrossRefPubMed
12.
go back to reference Jansen K, Brockmeyer NH, Hahn M, Kaul I, Fenske S, Rausch M, Kuhlmann B, Ulmer A, Lauenroth-Mai E, Harrer T, Hower M, Skaletz-Rorowski A, Michalik C: Competence network for HIV/AIDS. Epidemiological composition, clinical and treatment characteristics of the patient cohort of the German Competence Network for HIV/AIDS. Eur J Med Res 2009, 14: 415–425.PubMedCentralCrossRefPubMed Jansen K, Brockmeyer NH, Hahn M, Kaul I, Fenske S, Rausch M, Kuhlmann B, Ulmer A, Lauenroth-Mai E, Harrer T, Hower M, Skaletz-Rorowski A, Michalik C: Competence network for HIV/AIDS. Epidemiological composition, clinical and treatment characteristics of the patient cohort of the German Competence Network for HIV/AIDS. Eur J Med Res 2009, 14: 415–425.PubMedCentralCrossRefPubMed
13.
go back to reference Oette M, Kaiser R, Däumer M, Petch R, Fätkenheuer G, Carls H, Rockstroh JK, Schmalöer D, Stechel J, Feldt T, Pfister H, Häussinger D, the RESINA Study Team: Primary HIV drug-resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006, 41: 573–581. 10.1097/01.qai.0000214805.52723.c1CrossRefPubMed Oette M, Kaiser R, Däumer M, Petch R, Fätkenheuer G, Carls H, Rockstroh JK, Schmalöer D, Stechel J, Feldt T, Pfister H, Häussinger D, the RESINA Study Team: Primary HIV drug-resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006, 41: 573–581. 10.1097/01.qai.0000214805.52723.c1CrossRefPubMed
Metadata
Title
Ambulatory care for HIV-infected patients: differences in outcomes between hospital-based units and private practices: analysis of the RESINA cohort
Authors
Mark Oette
Stefan Reuter
Rolf Kaiser
Björn Jensen
Thomas Lengauer
Gerd Fätkenheuer
Heribert Knechten
Martin Hower
Abdurrahman Sagir
Herbert Pfister
Dieter Häussinger
the RESINA study group
Publication date
01-12-2013
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2013
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/2047-783X-18-48

Other articles of this Issue 1/2013

European Journal of Medical Research 1/2013 Go to the issue